| |
|
New Global Hepatitis Funding - HCV-HBV-NASH-HCV/HIV Coinfection – Screening, Care , Linkage to Care
|
| |
| |
Gilead Sciences today announced the launch of five new global programs to continue to support investigator-sponsored research in chronic hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV and HIV co-infection, nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). The programs will accept applications from around the world for projects that seek to address pressing unmet patient needs in liver disease, including improving screening and linkage to care, simplifying HCV testing and treatment, developing innovative referral pathways to help patients with NASH access care, addressing gaps in HBV care for special populations, and understanding PSC epidemiology.
The new grant programs are:
• HCV STAT (Simplification and Test and Treat Strategies toward HCV Elimination)
This program will fund approximately fifteen projects with a total budget of US $10M focused on simplifying HCV care delivery and implementing test and treat strategies to overcome barriers to patient care. STAT is the latest addition to the LEGA-C platform, “Local Elimination Programs Leading to Global Action in HCV” which includes the ongoing programs CITE, SCALE, CHIME, and NoCo. To date, Gilead has supported 79 elimination projects globally for $50M through LEGA-C. Applications will be accepted from April 11 to June 30, 2019.
• HIV/HCV NoCo (No Co-Infection)
In the third installment of NoCo, this program will fund approximately six to eight projects with a total budget of US $3M focused on investigating strategies to link patients living with HCV and HIV co-infection to curative HCV treatment. Applications will be accepted from May 1 to June 14, 2019.
• NASH Models of Care
This program will fund approximately eight to ten projects with a total budget of US $4M focused on investigating care pathways between multidisciplinary providers for screening, identifying, referring and treating high-risk patients living with NASH. Applications will be accepted from June 3 to July 15, 2019.
• HBV CARE (Linkage to CARe & Epidemiology in Special Populations)
This program will fund approximately six projects with a total budget of US $1M focused on improving linkage to care among underserved population and analyzing or identifying data gaps in HBV epidemiology in specific demographics or geographies. Applications will be accepted from August 1 to September 15, 2019.
• PSC PACE (PrimAry Sclerosing Cholangitis Epidemiology)
This program will fund up to five projects with a total budget of US $1M focused on identifying gaps in PSC epidemiology data and improving understanding of the cascade of care. Applications will be accepted from September 16 to October 11, 2019.
For more information on Gilead’s new liver disease grants programs, please visit https://www.gilead.com/science-and-medicine/research/investigator-sponsored-research.
| |
| |
| |
|
|
|
